Digest Network Come funziona
Network
/
Società
Ki
Non verificato

Kivu Bioscience

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

5 comunicati stampa

Guarda tutti i comunicati
12/01/2026
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors
Fonte
Kivu Bioscience
Emittente
Business Wire
1.00
0
27/10/2025
Kivu Bioscience Appoints Sophia Randolph, M.D., Ph.D., as Chief Medical Officer
Fonte
Kivu Bioscience
Emittente
Business Wire
1.00
0
20/10/2025
Oncologia
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Kivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025
Fonte
Kivu Bioscience
Emittente
Business Wire
1.00
0
02/06/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato del lavoro
Kivu Bioscience Selects Sterling Pharma Solutions for cGMP Manufacturing of Lead Oncology Antibody-Drug Conjugate KIVU-107
Fonte
Kivu Bioscience
Emittente
Business Wire
1.00
0
28/10/2024
Scienza
Biotecnologia
Medicina - Varie
Salute
Farmaceutica
Oncologia
Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates
Fonte
Kivu Bioscience
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0